Emergent BioSolutions (NYSE: EBS) will further develop a licensed drug against Ebola under a potential 10-year, $704 million contract from
Two Battelle employees have helped the National Institute of Allergy and Infectious Diseases conduct training for local researchers and teams
The Department of Health and Human Services has awarded Profectus BioSciences an $8.6 million contract to further develop and test
The GovCon Index entered Wednesday trading at 62.785 — approximately 0.82 percent higher than Tuesday’s figure, or an increase of 0.52.
The GovConIndex followed the other three major stock indices with a 1 percent decline from Friday’s figures as it closed
